Effektivnost', bezopasnost' i perspektivy dlitel'nogo ispol'zovaniya tadalafila v rezhime odin raz v den' u patsientov s erektil'noy disfunktsiey


Cite item

Full Text

About the authors

A V Zhivov

Email: andros1@rol.ru

References

  1. Guay A. T. ED2: erectile dysfunction = endothelial dysfunction. Endocrinol. Metab. Clin. N. Am. 2007; 36: 453-465.
  2. Watts G. F., Chew K. K., Stuckey B. G. The erectile-endothelial dysfunction nexus: new opportunities for cardiovascular risk prevention. Nat. Clin. Pract. Cardiovasc. Med. 2007; 4 (5): 263-273.
  3. Braun M., Wassmer G., Klotz T. et al. Epidemiology of erectile dysfunction: Results of the Cologne Male Survey. In. J. Impot. Res. 2000; 12: 305-311.
  4. Ponholzer A., Temml C., Mock K. et al. Prevalence and risk factors for erectile dysfunction in 2869 men using a validated questionnaire. Eur. Urol. 2005; 47: 80-86.
  5. Cialis® (tadalafil) Product Monograph, Eli Lilly Canada Inc. June 25, 2007.
  6. Hanson-Divers C., Jackson S. E., Lue T. F. Health outcomes variables important to patients in the treatment of erectile dysfunction. J. Urol. (Baltimore) 1998; 159: 1541-1547.
  7. Hackett G. I. Patient preferences in treatment of erectile dysfunction: the continuing importance of patient education. Clin. Cornerstone 2005; 7: 57-65.
  8. Leyva M. J. Erectile dysfunction. Perception of sexuality among men who suffer it. Rev. Enferm. 2006; 29: 64-68.
  9. Elia D., Grivel T., Lachowsky M. et al. Erectile dysfunction drugs and women. Gynecol. Obstet. Fertil. 2005; 33: 590-593.
  10. Simonelli C. Men's psychological experience with erectile dysfunction: a multi-ethic survey. In: 2-nd World congress on men's health 2002; October 25-27, 2002 in Vienna, Austria. Vienna; 2002. 53.
  11. Vignozzi L., Filippi S., Morelli A. et al. Effect of chronic tadalafil adminisration on penile hypoxia induced by cavernous neurotomy in the rat. J. Sex. Med. 2006; 3 (3): 419-431.
  12. Heaton J. P. W. The motion: There is a role for chronic treatment with PDE5-inhibitors. Eur. Urol. 2006; 49: 749-753.
  13. McMahon C. G. Treatment of erectile dysfunction with chronic dosing of tadalafil. Eur. Urol. 2006; 50: 215-217.
  14. Hatzimouratidis K., Hatzichristou D. Phosphodiesterase type 5 inhibitors: The day after. Eur. Urol. 2007; 51: 75-89.
  15. McMahon C. Efficacy and safety of daily tadalafil in men with erectile dysfunction previously unresponsive to on-demand tadalafil. J. Sex. Med. 2004; 1: 292-300.
  16. McMahon C. Comparison of efficacy, safety, and tolerability of on-demand tadalafil and daily dosed tadalafil for the treatment of erectile dysfunction. J. Sex. Med. 2005; 2: 415-427.
  17. Forgue S. T., Patterson B. E., Bedding A. W. et al. Tadalafil pharmacokinetics in healthy subjects. Br. J. Clin. Pharmacol. 2006; 61: 280-288.
  18. Porst H., Giuliano F., Glina S. et al. Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5 mg and 10 mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. Eur. Urol. 2006; 50: 351-359.
  19. Patterson B., Bedding A. W., Jewel H. et al. Dose-normalized pharmacokinetics of tadalafil (IC351) administered as a single dose to healthy volunteers. Int. J. Impot. Res. 2001; 13: S63.
  20. Rajfer J., Aliotta P. J., Steidle C. P. et al. Tadalafil dosed once a day in men with erectile dysfunction: A randomized, double-blind, placebo-controlled study in the US. Int. J. Impot. Res. 2007; 19: 95-103.
  21. Hatzichristou D., Gambla M., Rubio-Aurioles E. et al. Efficacy of tadalafil once daily in men with diabetes mellitus and erectile dysfunction. Diabet. Med. 2008; 25: 138-146.
  22. Porst H., Rafjer J., Casabe A. et al. Long-term safety and efficacy of 5 mg tadalafil dosed once daily in men with erectile dysfunction. Presented at he 10-th congress of the European society for sexual medicine; November 25-28, 2007, Lisbon, Portugal.
  23. Aversa A., Greco E., Bruzziches R. et al. Relationship between chronic tadalafil administration and improvement of endothelial function in men with erectile dysfunction: a pilot study. Int. J. Impot. Res. 2007; 19 (2): 200-207.
  24. Lysiak J. J., Yang S. K., Klausner A. P. et al. Tadalafil increases Akt and extracellular signal-regulated kinase 1/2 activation, and prevents apoptotic cell death in the penis following denervation. J. Urol. (Baltimore) 2008; 179 (2): 779-785.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2009 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies